Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Northwell Health Physician Partners at Flushing — Flushing, New York
- Northwell Health Physicians Partners Radiation Medicine at Queens — Forest Hills, New York
Phase 3 Recruiting Academic/Other
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health Physicians Partners Radiation Medicine at Queens — Forest Hills, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- Manhattan Eye Ear and Throat Hospital — New York, New York
- Lenox Hill Hospital — New York, New York
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- NYU Langone Hospital - Long Island — Mineola, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Bronx Veterans Affairs Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…
Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in New York: - Research Site — New York, New York
- Research Site — Syracuse, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in New York: - Northwell Health Cancer Institute — Lake Success, New York
- Manhattan Eye, Ear & Throat Hospital — New York, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in New York: - Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009) — New York, New York
Phase 2, Phase 3 Recruiting Industry
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …
Sponsor: BioNTech SE
NCT ID: NCT04534205
Sites in New York: - Memorial Sloan Kettering Cancer Center — Long Island City, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Sites in New York: - Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
- Garnet Health Medical Center — Middletown, New York
- Long Island Jewish Medical Center — New Hyde Park, New York
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in New York: - Northwell Health/Center for Advanced Medicine — Lake Success, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 2 Recruiting Academic/Other
This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…
Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in New York: - Montefiore Medical Center-Einstein Campus — The Bronx, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
Phase 2 Recruiting NIH
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in New York: - Stony Brook University Medical Center — Stony Brook, New York
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in New York: - Local Institution - 2117 — New York, New York
- Local Institution - 1002 — New York, New York
- Local Institution - 2102 — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in New York: - Columbia University — New York, New York
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in New York: - NYU Langone Health — New York, New York
- Icahn School of Medicine At Mount Sinai Prime — New York, New York
- Clinical Research Alliance, Inc — Westbury, New York
- White Plains Hospital — White Plains, New York
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in New York: - Avenzo Therapeutics Recruiting Site — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in New York: - Memorial Sloan-Kettering Cancer Center — New York, New York
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New York: - Weill Cornell Medicine, Cornell University (site 126) — New York, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of…
Sponsor: Tubulis GmbH
NCT ID: NCT06657222
Sites in New York: - Mount Sinai — New York, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in New York: - NYU Langone Health — New York, New York
Phase 2 Recruiting Industry
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expr…
Sponsor: AstraZeneca
NCT ID: NCT04379596
Sites in New York: - Research Site — New York, New York
Phase 2 Recruiting Industry
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ot…
Sponsor: Matrix Biomed, Inc.
NCT ID: NCT03480971
Sites in New York: - Montefiore Medical Center-Einstein Campus — The Bronx, New York
Phase 2 Recruiting Academic/Other
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07063212
Sites in New York: - Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York, New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York